A crossover, randomized, two-sequence, 12 hour bioequivalence study in healthy volunteers to compare the pharmacokinetics, safety and tolerability of ND0701 with reference commercial apomorphine product

Trial Profile

A crossover, randomized, two-sequence, 12 hour bioequivalence study in healthy volunteers to compare the pharmacokinetics, safety and tolerability of ND0701 with reference commercial apomorphine product

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Jun 2017

At a glance

  • Drugs Apomorphine (Primary)
  • Indications Parkinson's disease
  • Focus First in man; Pharmacokinetics
  • Most Recent Events

    • 08 Jun 2017 Results presented at the 21st International Congress of Parkinson's Disease and Movement Disorders
    • 23 May 2017 According to a NeuroDerm media release, data from this trial will be presented at the 21st International Congress of Parkinson's Disease and Movement Disorders.
    • 02 Dec 2016 Based on the results of this study, NeuroDerm Ltd plans to pursue a PK similarity regulatory development route in the EU for ND0701 and meet with European regulatory authorities in the second half of 2017 to discuss its development strategy, as per a NeuroDerm media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top